367 related articles for article (PubMed ID: 9758317)
21. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Leonard SN; Rybak MJ
J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
[TBL] [Abstract][Full Text] [Related]
22. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
23. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
24. Vancomycin dosing for pneumonia in critically ill trauma patients.
Patanwala AE; Norris CJ; Nix DE; Kopp BJ; Erstad BL
J Trauma; 2009 Oct; 67(4):802-4. PubMed ID: 19820588
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
Burgess DS; Summers KK; Hardin TC
Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
[TBL] [Abstract][Full Text] [Related]
26. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
[TBL] [Abstract][Full Text] [Related]
27. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia.
Jaruratanasirikul S; Sriwiriyajan S; Ingviya N
J Pharm Pharmacol; 2002 Dec; 54(12):1693-6. PubMed ID: 12542901
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
Madrigal AG; Basuino L; Chambers HF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
[TBL] [Abstract][Full Text] [Related]
29. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of daptomycin against isolates of Staphylococcus aureus and enterococci: first results from Turkey.
Arslan H; Azap OK; Ergin F; Karaman SO; Oruç E
Int J Antimicrob Agents; 2004 Jun; 23(6):642-3. PubMed ID: 15194140
[No Abstract] [Full Text] [Related]
31. Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency.
Pai MP; Mercier RC; Allen SE
Ann Pharmacother; 2006 Mar; 40(3):553-8. PubMed ID: 16507618
[TBL] [Abstract][Full Text] [Related]
32. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
Carpenter CF; Chambers HF
Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832
[TBL] [Abstract][Full Text] [Related]
33. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia.
Sakoulas G; Gold HS; Cohen RA; Venkataraman L; Moellering RC; Eliopoulos GM
J Antimicrob Chemother; 2006 Apr; 57(4):699-704. PubMed ID: 16464892
[TBL] [Abstract][Full Text] [Related]
34. Vancomycin: we can't get there from here.
Patel N; Pai MP; Rodvold KA; Lomaestro B; Drusano GL; Lodise TP
Clin Infect Dis; 2011 Apr; 52(8):969-74. PubMed ID: 21460308
[TBL] [Abstract][Full Text] [Related]
35. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
Frymoyer A; Guglielmo BJ; Hersh AL
Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
[TBL] [Abstract][Full Text] [Related]
36. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.
Burgess DS; Hastings RW; Hardin TC
Clin Ther; 2000 Jan; 22(1):66-75. PubMed ID: 10688391
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections.
Verrall AJ; Llorin R; Tam VH; Lye DC; Sulaiman Z; Zhong L; Archuleta S; Fisher DA
J Antimicrob Chemother; 2012 Dec; 67(12):2970-3. PubMed ID: 22915464
[TBL] [Abstract][Full Text] [Related]
40. [Adequate intrathecal diffusion of teicoplanin after failure of vancomycin, administered in continuous infusion in three cases of shunt associated meningitis].
Jourdan C; Convert J; Peloux A; Boussaid O; Grando J; Tigaud S
Pathol Biol (Paris); 1996 May; 44(5):389-92. PubMed ID: 8758482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
